The emerging role for type 5 phosphodiesterase inhibition in heart failure

Current Heart Failure Reports

Volumn 3, Issue 3, 2006, Pages 123-128

  Lewis, Gregory D ^b   Semigran, Marc J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR; CYCLIC GMP; EMD 92639; NIFEDIPINE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL; WARFARIN;

APOPTOSIS; BLOOD VESSEL TONE; CATABOLISM; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; EXERCISE; FLUSHING; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART AFTERLOAD; HEART FAILURE; HEART HYPERTROPHY; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; IC 50; LONG TERM CARE; LUNG BLOOD VESSEL; MUSCLE BLOOD VESSEL; NONHUMAN; PATIENT SAFETY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VASODILATATION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; EXERCISE TOLERANCE; HEART; HEART FAILURE, CONGESTIVE; HUMANS; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; VASODILATION;

EID: 33845421962     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-006-0011-0     Document Type: Review

References (51)

1. Beavo JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995, 75:725-748.
2. Wallis RM, Corbin JD, Francis SH, et al.: Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999, 83:3C-12C.
3. Semigran MJ: Type 5 phosphodiesterase inhibition: the focus shifts to the heart. Circulation 2005, 112:2589-2591.
4. Maurice DH, Palmer D, Tilley DG, et al.: Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003, 64:533-546.
5. Reffelmann T, Kloner RA: Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003, 108:239-244.
6. Kloner RA: Cardiovascular Effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004, 110:3149-3155.
7. Gresser U, Gleiter CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res 2002, 7:435-446.
8. Colucci WS, Jaski BE, Fifer MA, et al.: Milrinone: a positive inotropic vasodilator. Trans Assoc Am Physicians 1984, 97:124-133.
9. Burstein S, Semigran MJ, Dec GW, et al.: Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure. J Am Coll Cardiol 1992, 20:822-829.
10. Katz SD, Balidemaj K, Homma S, et al.: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000, 36:845-851.
11. Treasure CB, Alexander RW: The dysfunctional endothelium in heart failure. J Am Coll Cardiol 1993, 22:129A-134A.
12. Porter TR, Taylor DO, Cycan A, et al.: Endothelium-dependent pulmonary artery responses in chronic heart failure influence of pulmonary hypertension. J Am Coll Cardiol 1993, 22:1418-1424.
13. Di Salvo TG, Mathier M, Semigran MJ, et al.: Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995, 25:1143-1153.
14. Franciosa JA, Baker BJ, Seth L: Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J 1985, 110:807-813.
15. Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718-1723.
16. Loh E, Stamler JS, Hare JM, et al.: Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994, 90:2780-2785.
17. Semigran MJ, Cockrill BA, Kacmarek R, et al.: Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 1994, 24:982-988.
18. Koelling TM, Kirmse M, Di Salvo TG, et al.: Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 1998, 81:1494-1497.
19. Rabe KF, Tenor H, Dent G, et al.: Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994, 266:L536-L543.
20. Galiè N, Ghofrani HA, Torbicki A: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
21. Cockrill BA, Kacmarek RM, Fifer MA, et al.: Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001, 119:128-136.
22. Burstein S, Semigran MJ, Dec GW, et al.: Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure. J Am Coll Cardiol 1992, 20:822-829.
23. Hare JM, Kim B, Flavahan NA, et al.: Pertussis toxin-sensitive G proteins influence nitric oxide synthase III activity and protein levels in rat heart. J Clin Invest 1998, 101:1424-1431.
24. Mery PF, Pavoine C, Belhassen L, et al.: Nitric oxide regulates cardiac Ca2+ current: involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylate cyclase activation. J Biol Chem 1994, 268:26286-26295.
25. Mery P, Lohmann SM, Walter U, Fischmeister R: Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 1991, 88:1197-1201.
26. Trautwein W, Trube G: Negative inotropic effects of cyclic GMP in cardiac fiber fragments. Pflugers Arch 1976, 366:293-295.
27. Hare JM, Loh E, Creager MA, Colucci WS: Nitric oxide inhibits the positive inotropic response to β-adrenergic stimulation in humans with left ventricular dysfunction. Circulation. 1995, 92:2198-2203.
28. Castro LRV, Verde I, Dermot MF, et al.: Cyclic guanosine monophosphate compartmentalization in rat cardiac myocytes. Circulation 2006, 113:2221-2228.
29. Kotera J, Fujishige K, Akatsuka H, et al.: Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 1998, 273:26982-26990.
30. Yanaka N, Kotera J, Ohtsuka A, et al.: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998, 255:391-399.
31. Maurice DH, Palmer D, Tilley DG: Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 2003, 64:533-546.
32. Senzaki H, Smith CJ, Juang GJ, et al.: Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 2001, 15:1718-1726.
33. Takimoto E, Champion HC, Belardi D, et al.: cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 2005, 96:100-109.
34. Ziolo MT, Lewandowski SJ, Smith JM, et al.: Inhibition of cyclic GMP hydrolysis with zaprinast reduces basal and cyclic AMP-elevated L-type calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 2003, 138:986-994.
35. Borlaug BA, Melenovsky V, Marhin T, et al.: Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 2005, 112:2642-2649. Healthy human subjects receiving sildenafil demonstrated diminished dobutamine-induced augmentation of contractility as measured by peak power index and LV ejection fraction. These findings suggest that increasing intracellular cGMP in cardiomyocytes, through inhibition of PDE5, may act as a brake on β-adrenergic signaling by counteracting calcium release from the sarcoplasmic reticulum.
36. Takimoto E, Champion HC, Li M, et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
37. Narula J, Haider N, Virmani R, et al.: Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996, 335:1182-1189.
38. Singal PK, Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
39. Ockaili R, Salloum F, Hawkins J, Kukreja RC: Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002, 283:H1263-H1269.
40. Kumar D, Kirshenbaum LA, Li T, et al.: Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 2001, 3:135-145.
41. Salloum F, Yin C, Xi L, Kukreja RC: Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003, 92:595-597.
42. Fisher PW, Salloum F, Das A, et al.: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 2005, 111:1601-1610.
43. Lepore JJ, Maroo A, Pereira NL, et al.: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127:1647-1653.
44. Guazzi M, Tumminello G, Di Marco F, et al.: The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004, 44:2339-2348.
45. Guazzi M, Tumminello G, Di Marco F, Guazzi MD: Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther 2004, 76:371-378.
46. Lewis GD, Lachman J, Camuso J, et al.: Sildenafil improves hemodynamics and exercise tolerance in patients with advanced heart failure. Circulation 2006, In press.
47. Bocchi EA, Guimaraes G, Mocelin A, et al.: Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002, 106:1097-1103.
48. Cohn JN, Archibald DG, Ziesche S, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547-1552.
49. Cheitlin MD, Hutter AM Jr, Brindis RG, et al.: Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999, 99:168-177.
50. Webster LJ, Michelakis ED, Davis T, et al.: Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. Arch Intern Med 2004, 164:514-520.
51. Katz SD, Parker JD, Glasser DB, et al.: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and chronic heart failure. Am J Cardiol 2005, 95:36-42.